Latest Period
Q1 2026
Security Snapshot
TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 Institutional Ownership
CUSIP: 89422GAA5
13F Institutional Holders and Ownership History from Q1 2022 to Q1 2026
Institutions Reporting
27
Principal
$317,235,000
Price (% of par)
126.25%
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Debt / NOTE 2.250% 3/0
- Market price (% of par)
- 126.25%
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F principal
- $317,235,000
- Total reported market value
- $401,223,699
- Principal change
- +$503,000
- Market value change
- -$5,435,851
- Number of holders
- 27
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- 89422GAA5 - TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 is tracked under CUSIP 89422GAA5.
- 27 institutions reported positions in Q1 2026.
- Schedule 13D/13G significant owner rows are not currently available.
Change
- Holder count moved from 33 to 27 between Q4 2025 and Q1 2026.
- Reported value moved from $451,855,340 to $401,223,699.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 27 institutions filings for Q1 2026.
Security key
89422GAA5
Latest holder period
Q1 2026
13F holders
27
13D/G owners
0
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 89422GAA5:
As of 31 Mar 2026, 27 institutional investors reported holding $317,235,000 in principal (par value) of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0.
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 across Reporting Periods
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | $317,235,000 | $401,223,699 | -$5,435,851 | 126.25% | 27 |
| 2025 Q4 | $316,740,000 | $451,855,340 | +$76,789,651 | 142.2% | 33 |
| 2025 Q3 | $272,401,354 | $307,917,277 | +$569,773 | 112.88% | 29 |
| 2025 Q2 | $279,664,978 | $303,344,890 | +$1,782,692 | 95.39% | 26 |
| 2025 Q1 | $277,011,293 | $276,983,110 | +$13,929,020 | 99.8% | 28 |
| 2024 Q4 | $264,062,863 | $250,352,690 | +$9,069,609 | 95.24% | 21 |
| 2024 Q3 | $257,683,037 | $224,077,029 | +$11,645,577 | 86.4% | 25 |
| 2024 Q2 | $253,865,742 | $203,588,240 | -$12,098,839 | 64.79% | 18 |
| 2024 Q1 | $273,167,017 | $213,304,940 | -$34,119,308,890 | 63.47% | 18 |
| 2023 Q4 | $334,700,000 | $220,380,890 | +$27,118,701 | 66.0% | 20 |
| 2023 Q3 | $293,624,167 | $216,434,339 | +$1,578,777 | 64.72% | 22 |
| 2023 Q2 | $302,112,167 | $244,546,345 | -$10,623,621 | 81.08% | 21 |
| 2023 Q1 | $312,983,167 | $325,418,603 | +$10,031,881 | 98.3% | 21 |
| 2022 Q4 | $301,166,967 | $274,825,761 | -$26,924,802 | 91.19% | 21 |
| 2022 Q3 | $282,429,300 | $289,316,637 | -$825,518 | 102.07% | 23 |
| 2022 Q2 | $239,416,100 | $244,284,801 | -$22,593,875 | 100.32% | 21 |
| 2022 Q1 | $257,273,349 | $279,703,965 | +$279,703,965 | 106.45% | 23 |